Filamon is an Australian, public, unlisted drug development company focused on the development of next generation anti-inflammatory drugs for age-related chronic inflammatory diseases. The target is degenerative diseases accounting for most hospitalisations and deaths in developed countries. The target indications are solid cancers, ophthalmic diseases including wet AMD and dry AMD, and neurological diseases associated with neuroinflammation. The Company’s focus is on providing the aging population with a renewed chance for more productive and independent living. Through groundbreaking research and technology, we are reshaping what it means to treat age-related chronic diseases.

Filamon Limited

Org chart

Teams

Offices